Adamantinoma
A rare bone tumor
Adamantinoma is a rare, low-grade malignant bone tumor that primarily affects the tibia. It is characterized by its slow growth and potential to metastasize, particularly to the lungs.
Epidemiology
Adamantinoma accounts for less than 1% of all primary bone tumors. It most commonly occurs in young adults, with a slight male predominance. The typical age of onset is between 20 and 40 years.
Pathophysiology
The exact cause of adamantinoma is unknown. Histologically, it is characterized by epithelial-like cells within a fibrous stroma. The tumor is thought to arise from remnants of the epithelial cells in the periosteum or from mesenchymal cells that have undergone epithelial differentiation.
Clinical Presentation
Patients with adamantinoma typically present with a long history of pain and swelling in the affected limb. The tibia is the most common site, but it can also occur in the fibula and other bones. The pain is often insidious and may be associated with a palpable mass.
Diagnosis
Diagnosis of adamantinoma is based on a combination of clinical, radiological, and histological findings.
Imaging
X-ray imaging typically shows a well-defined, lytic lesion in the diaphysis of the tibia with cortical involvement. Advanced imaging techniques such as MRI and CT scan can further delineate the extent of the tumor and its relationship to surrounding structures.
Histology
Histological examination reveals nests and cords of epithelial cells within a fibrous stroma. Immunohistochemical staining is often used to confirm the diagnosis.
Treatment
The primary treatment for adamantinoma is surgical resection. Wide local excision with clear margins is the treatment of choice to minimize the risk of recurrence. In some cases, limb-sparing surgery or amputation may be necessary.
Prognosis
The prognosis for patients with adamantinoma is generally favorable if the tumor is completely resected. However, local recurrence and metastasis can occur, necessitating long-term follow-up.
Related pages
Gallery
-
Histological image of adamantinoma
-
X-ray showing adamantinoma of the tibia
-
Adamantinoma
-
X-ray of adamantinoma of the tibia
Ad. Transform your life with W8MD's Budget GLP-1 injections from $29.99


W8MD offers a medical weight loss programs including NYC medical weight loss and Philadelphia medical weight loss offering:
- Budget GLP1 shots (generic and brand names) such as
- Learn more: Budget GLP1 weight loss injections NYC & Philadelphia GLP1 weight loss shots
- Most insurances accepted
- Budget GLP1 weight loss injections such as Semaglutide starting from $29.99/week and $45.00/week (Tirzepatide) with insurance.
NYC weight loss doctor appointmentsNYC weight loss doctor appointments
Start your NYC weight loss journey today at our:
- Call 718-946-5500 for NYC or 215-676-2334 for Philadelphia
- Tags:
GLP1 weight loss doctor NYC, Zepbound NYC, Budget GLP1 weight loss injections, Philadelphia medical weight loss, Wegovy NYC, Brooklyn weight loss, Wegovy NYC, Budget GLP1 shots NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian